Matrix metalloproteinase-11 (MMP11) mRNA (MMP11)

Matrix metalloproteinase-11 (MMP11), also known as stromelysin-3, is a zinc-dependent endopeptidase that plays a unique role in the matrix metalloproteinase family (UniProt P24347). Unlike other MMPs that are secreted as inactive zymogens requiring extracellular activation, MMP11 is processed intracellularly by furin-like proprotein convertases and secreted as an active enzyme (PubMed: 25611381). It is predominantly expressed by stromal cells, particularly peritumoral fibroblasts, rather than the cancer cells themselves, facilitating a supportive microenvironment for tumor invasion (PubMed: 11091208). MMP11 promotes malignancy by degrading specific substrates like alpha-1 antitrypsin and collagen VI, which in turn supports cancer cell survival and suppresses adipocyte differentiation (PubMed: 22430211). In clinical practice, MMP11 mRNA levels serve as a critical prognostic biomarker, most notably as one of the 21 genes in the Oncotype DX assay used to predict breast cancer recurrence (Genomic Health). Because traditional small-molecule inhibitors of MMPs have largely failed in clinical trials due to lack of specificity, modern therapeutic efforts have shifted toward targeting MMP11 mRNA directly using RNA interference (RNAi) or antisense oligonucleotides (PubMed: 22430211). These mRNA-targeted approaches aim to selectively downregulate MMP11 expression to halt tumor progression and metastasis while minimizing systemic toxicity. Experimental studies have demonstrated that silencing MMP11 mRNA can significantly reduce tumor volume and invasive potential in various cancer models (PubMed: 22430211).

Other names

Stromelysin-3SL-3ST3Matrix metallopeptidase 11

Antisense inhibition or RNA interference (RNAi) targeting the MMP11 transcript to prevent protein synthesis.